AbbVie raised its 2026 full-year adjusted earnings guidance to $13.95–$13.99 per share on October 30, 2026, after topping third-quarter expectations with $17.40 billion in revenue. Strong demand for immunology drugs Skyrizi ($5.78 billion) and Rinvoq ($2.71 billion), along with a 19% rise in neuroscience sales to $3.39 billion, helped offset revenue drops from Humira and pushed AbbVie shares up 27% in 2026.
Raised full-year profit forecast
- ▪AbbVie also raised its quarterly dividend alongside boosting its full-year 2026 profit outlook on October 30, 2026
- ▪AbbVie's raised 2026 profit forecast includes a 69-cent per share negative impact from acquired in-process research and development and milestone expenses booked through the third quarter of 2026
- ▪AbbVie raised its full-year 2026 adjusted earnings forecast to $13.95 to $13.99 per share, up from its prior projection of $13.76 to $13.96 per share
Third-quarter financial results and stock reaction
- ▪AbbVie's neuroscience portfolio revenue grew 19% to $3.39 billion in the third quarter of 2026, driven by Botox Therapeutic and antipsychotic drug Vraylar
- ▪AbbVie reported third-quarter 2026 revenue of $17.40 billion and adjusted earnings of $3.82 per share, with both figures topping analyst estimates
- ▪AbbVie shares rose about 1% on October 30, 2026 following its earnings report, bringing its total share price growth to approximately 27% for 2026 to reach record highs
Immunology drug sales and portfolio
- ▪Rinvoq is indicated to treat a range of inflammatory joint, skin, and gastrointestinal conditions
- ▪Investors expect sales of AbbVie's newer immunology drugs Skyrizi and Rinvoq to offset declining revenue from its former flagship drug Humira
- ▪AbbVie's inflammatory condition drug Rinvoq generated $2.71 billion in third-quarter 2026 revenue, meeting analyst expectations
- ▪AbbVie's immunology drug Skyrizi recorded $5.78 billion in third-quarter 2026 sales, reflecting a 22.7% increase from the prior year and beating Wall Street estimates of $5.75 billion
Development of experimental treatments
- ▪AbbVie is developing ABBV-295, an experimental weight-loss treatment that it licensed in 2025 from Danish biotech company Gubra
- ▪AbbVie is advancing lutikizumab, an experimental skin disease treatment, to broaden its immunology product franchise
Story comments
Loading comments…